Fluconazole: An Update of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Major Superficial and Systemic Mycoses in Immunocompromised Patients

Drugs

Volumn 50, Issue 4, 1995, Pages 658-690

  Goa, Karen L ^a   Barradell, Lee B ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CLOTRIMAZOLE; CYCLOSPORIN; CYTOCHROME P450; FLUCONAZOLE; FLUCYTOSINE; GLIBENCLAMIDE; GLIPIZIDE; ITRACONAZOLE; KETOCONAZOLE; LIVER ENZYME; MICONAZOLE; NYSTATIN; PHENYTOIN; RIFABUTIN; RIFAMPICIN; SULFONYLUREA; TERFENADINE; THEOPHYLLINE; TOLBUTAMIDE; WARFARIN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLEEDING; BONE MARROW TRANSPLANTATION; CANCER; CANDIDIASIS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESISTANCE; FUNGAL MENINGITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGLYCEMIA; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER DYSFUNCTION; MORTALITY; MYCOSIS; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; RASH; REVIEW; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMAL; ANTIFUNGAL AGENTS; CHILD; COMPARATIVE STUDY; FLUCONAZOLE; HIV INFECTIONS; HUMAN; IMMUNOCOMPROMISED HOST; MYCOSES; NEOPLASMS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029083034     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199550040-00007     Document Type: Article

References (204)

1. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses
2. Fluconazole: an update of its antimicrobial activity, pharmacokinetic properties and therapeutic use in vaginal candidiasis
3. Antifungal chemotherapy in patients with acquired immunodeficiency syndrome
4. Importance of Candida species other than C. albicans as pathogens in oncology patients
5. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, doubleblind, multicenter trial
6. Antifungal prophylaxis in bone marrow transplantation
7. Coccidioidmycosis
8. Standardized susceptibility testing of fluconazole: an International Collaborative study
9. Fluconazole therapy intransplant recipients receiving FK506
10. Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates
11. Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans
12. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole verusus amphotericin B as treatment of nonneutropenic patients with candidemia
13. Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods
14. Improved medium for fluconazole susceptibility testing of Candida albicans
15. Comparison of fluconazole minimum inhibitory concentrations in three different formulations of RPMI-1640
16. Evaluation of 80% inhibition standards for the determination of fluconazole minimum inhibitory concentrations in three laboratories
17. Correlation between in vitro and in vivo activity of antifungal agents against Candida species
18. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection
19. Fluconazole-resistant candidosis in an HIV cohort
20. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients
21. Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients
22. Correlation of m vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1
23. In vitro susceptibility of fungal isolates of clinically important specimens to itraconazole, fluconazole and amphotericin B
24. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation — a prospective, randomized, double-blind study
25. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
26. In vitro susceptibility testing of Candida isolates from clinical specimens to four antifungal agents
27. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole
28. Comparative sensitivity of yeasts to ketoconazole, itraconazole and fluconazole with a liquid medium standardized micromethod [in French]
29. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period
30. In vitro susceptibility to fluconazole of fungal strains freshly isolated from child patients with deep-seated mycoses [in Japanese]
31. Efficacies of amphotericin B-desoxychol-ate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice
32. Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis
33. Comparison of SCH 39304, fluconazole, and ketoconazole for treatment of systemic infections in mice
34. Comparison of the efficacy of cilofungin, fluconazole and amphotericin B in the treatment of systemic Candida albicans infection in the neutropenic mouse
35. Efficacy of prophylactic and early fluconazole treatment on systemic candidiasis in experimentally neutropenic rabbits
36. Comparison of fluconazole with amphotericin B in treatment of histoplasmosis in normal and immunosuppressed mice
37. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis
38. Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice
39. Resistance of Candida species to fluconazole
40. Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole
41. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis
42. Fluconazole-resistant Candida albicans
43. Fluconazole-resistant Candida in AIDS patients
44. Fluconazole resistant Candida in AIDS [letter; comment]
45. Fluconazole-resistant Candida albicans after long-term suppressive therapy
46. Fluconazole resistant Candida in AIDS
47. Fluconazole resistance in AIDS patients
48. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS
49. Oro-esophageal candidiasis resistant to fluconazole in patients with AIDS [in Spanish]
50. Candida albicans resistance in AIDS [letter] [see comments]
51. Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole
52. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis
53. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole
54. Molecular epidemiology of Candida isolates from AIDS patients showing different fluconazole resistance profiles
55. DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS
56. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis
57. Fluconazole-resistant Cryptococcus neoformans var gattii in an AIDS patient
58. Failure of fluconazole treatment in cryptococcal meningitis despite adequate CSF levels
59. Prophylactic fluconazole and Candida krusei infections
60. Selection of Candida glabrata in pdiatric bone marrow transplant recipients receiving fluconazole
61. Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia, and typhlitis
62. Fluconazole and Candida krusei infections
63. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole [letter]
64. Increase in Candida krusei infection among patients with bone marrow transplan-tation and neutropenia treated prophylactically with fluconazole
65. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
66. Effect of fluconazole on the interactions between human neutrophils and Candida albicans
67. Effects of azole antifungals in vitro on host/parasite interactions relevant to Candida infections
68. In vitro effects of fluconazole (UK-49,858) and ketoconazole on mouse lymphocyte proliferation and on Candida blastospore destruction by human polymor-phonuclear leukocytes
69. Immunometabolic monitoring in patients with candidosis treated with fluconazole [abstract]
70. Suppression of neutrophil and lymphoproliferative responses in vitro by itraconazole but not fluconazole
71. Comparison of the immunosuppressive activities of the antimycotic agents itraconazole, fluconazole, ketoconazole and miconazole on human T-cells
72. The effect of amphotericin B, miconazole and fluconazole on cellular components of the immune system in vivo [abstract]
73. Oral azole drugs as systemic antifungal therapy
74. Azole antifungal agents
75. Azoles, allylamines and drug metabolism
76. Drug interactions with fluconazole
77. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man
78. Comparative effects of imidazole antifungals on liver monoxygenases [abstract]
79. Pharmacokinetics and tissue penetration of fluconazole in humans
80. Clinical pharmacokinetics of fluconazole
81. Pharmacokinetics and bioavailability of fluconazole in patients with AIDS
82. Pharmacokinetic profile of fluconazole, a systemic antimycotic drug [in German]
83. The pharmacokinetics of fluconazole after a single intravenous dose in AIDS patients
84. Administration of the antimycotic agents fluconazole and itraconazole to leukaemia patients; a comparative pharmacokinetic study
85. Increased gastric pH and the bioavailability of fluconazole and ketoconazole
86. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole
87. Effect of oral antacid administration on the pharmacokinetics of oral fluconazole
88. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity
89. Pharmacokinetic optimisation of oral antifungal therapy
90. Vandenbroucke A. Pharmacokinetics of fluconazole in serum and cerebrospinal fluid in a patient with AIDS and cryptococcal meningitis
91. Treatment of two cases of cryptococcal meningitis with fluconazole
92. Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazole
93. Influence of local radiotherapy on penetration of fluconazole into human saliva
94. Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis
95. Pharmacokinetics of fluconazole in pediatrie patients
96. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases
97. Pharmacokinetics of prophylactic fluconazole in pediatric hematology/oncology patients [abstract]
98. Fluconazole and ketoconazole in the treatment of oral and esophageal candidiasis in AIDS patients
99. Treatment of oral Candida mucositis infections
100. An open assessment of the safety and efficacy of oral fluconazole in the treatment of oropharyngeal candidiasis in HIV infected patients [abstract]
101. Fluconazole in the treatment of oropharyngeal candidosis in HIV-positive patients
102. Fluconazole therapy of oral candidiasis in HIV-infected patients: results of a multicentre study
103. Oropharyngeal candidiasis in HIV-positive patients. Fluconazole in the treatment in registered practice [in German]
104. Fluconazole versus ketoconazole in the treatment of oropharyngeal candidiasis in HIV-infected children
105. Fluconazole or amphotericin B and flucytosine in the treatment of Candida oesophagitis in HIV-1-infected patients [in German]
106. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches
107. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS
108. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. Arandomized trial
109. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial
110. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-asso-ciated crytococcal meningitis
111. Eosphageal candidiasis in patients infected with the human immunodeficiency virus. A decision analysis to assess cost-effectiveness of alternative management strategies
112. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary
113. Clinical and mycological evaluation of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS patients: an open, multicenter study
114. Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients
115. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection
116. Treatment of oropharyngeal candidiasis in HIV-infected children with oral fluconazole
117. Cryptococcal meningitis and AIDS
118. Fluconazole treatment of persistent Cryptococus neoformans prostatic infection in AIDS
119. Cryptococcal meningitis associated with acquired immunodeficiency syndrome (AIDS) in African patients — treatment with fluconazole
120. High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection
121. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS
122. Management of cryptococcosis
123. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome
124. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome
125. Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients
126. Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis. Comparison of fluconazole and amphotericin B-based therapies
127. Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis [letter]
128. Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients
129. Histoplasmosis in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and fluconazole
130. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome
131. Fluconazole in the treatment of invasive candidal and cryptococcal infections in organ transplant recipients
132. Fluconazole in the treatment of fungal infections in kidney-transplanted patients
133. Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome
134. Fluconazole in the treatment of mycotic oropharyngeal stomatitis and esophagitis in neutropenic cancer patients
135. Treatment of Candida albicans fungaemia with fluconazole
136. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy
137. Hepatosplenic candidiasis: successful treatment with fluconazole
138. Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs. ketoconazole
139. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
140. Interventional treatment of unexplained fever (FUO) and documented infections in neutropenic patients with hématologic malignancies: fluconazole versus ampho-B/5-FC [abstract]
141. Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever — preliminary observations from a pilot, exploratory study
142. Prophylaxis of oropharyngeal candidiasis with fluconazole
143. The prophylactic use of fluconazole 50 vs. 100 mg daily in haematological malignancies [letter]
144. Antifungal prophylaxis during remission induction therapy for acute leukemia: fluconazole versus intravenous amphotericin B
145. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B
146. Chemoprophylaxis of fungal infections in granulocytopenic patients using fluconazole vs oral amphotericin B
147. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia
148. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies
149. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients
150. Fluconazole in patients at risk from invasive aspergillosis
151. Aspergillus fumigatus pneumonia in neutropenic patients during therapy with fluconazole for infection due to Candida species
152. Fluconazole in the treatment of candidiasis in immunocompromised children
153. Fluconazole treatment of children with severe fungal infections not treatable with conventional agents
154. Fluconazole prophylaxis and Candida fungemia in neutropenic children with malignancies
155. Fluconazole in children: first experience with prophylaxis in chemotherapy-induced neutropenia in pédiatrie patients with cancer
156. Human immunodeficiency virus (HIV) infection. Does it increase susceptibility to adverse drug reactions
157. Fluconazole-induced toxic epidermal necrolysis in a patient with human immunodeficiency virus infection
158. Stevens-Johnson syndrome after fluconazole
159. Adverse drug reactions to systemic antifungals. Prevention and management
160. Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome
161. Dose-dependent fluconazole heptatotoxcity proven on biopsy and rechallenge
162. Fatal acute hepatic necrosis due to fluconazole
163. Fluconazole-associated acute adrenal insufficiency
164. Induction of fluconazole metabolism by rifampin: in vivo study in humans
165. Interaction between fluconazole and rifampicin [letter]
166. Rifabutin does not alter fluconazole pharmacokinetics [abstract]
167. Fluconazole and enhanced effect of rifabutin prophylaxis [letter]
168. Effect of fluconazole on pharmacokinetics of 2′,3′-dideoxyinosine in persons séropositive for human immunodeficiency virus
169. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus
170. Interaction between cyclosporine and fluconazole in renal allograft recipients
171. Interaction between ciclosporine and fluconazole in a renal transplant [in Spanish]
172. Fluconazole-cyclosporine interaction: a dosedependent effect
173. Interaction of fluconazole with ciclosporin A [letter]
174. An evaluation of the effect of fluconazole on the stereoselective metabolism of warfarin [abstract]
175. Possible interaction between warfarin and fluconazole
176. Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium
177. Possible potentiation of warfarin by fluconazole
178. Case report: potentiation of warfarin by fluconazole
179. Effect of fluconazole on the disposition of phenytoin
180. Phenytoin toxicity induced by fluconazole [letter]
181. Fluconazole-induced symptomatic phenytoin toxicity
182. Hypoglycaemic coma in a patient treated with glipizide and fluconazole: a potential interaction? [in French]
183. Fluconazole-nortriptyline drug interaction
184. Effect of fluconazole on theophylline disposition in humans
185. The effect of fluconazole on the steady-state pharmacokinetics and electro-cardiographic pharmacodynamics of terfenadine in humans
186. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients
187. When to use fluconazole
188. Review: resistance of yeasts to azole-derivative antifungals
189. Fluconazole resistance in Candida in patients with AIDS — a therapeutic approach
190. Overview of fungal infections in cancer patients
191. The use of fluconazole prophylaxis in patients with chemotherapy-induced neutropenia
192. Primary prophylaxis against opportunistic infections in patients with AIDS